Verrica Pharmaceuticals's Ycanth offers superior efficacy to Novan, says Needham » 09:1806/1706/17/21
Needham analyst Serge…
Needham analyst Serge Belanger keeps his Buy rating and $22 price target on Verica Pharma (VRCA) after a recent phase 3 study report by its competitor Novan (NOVN) for SB206 - a topical once-daily antiviral gel in development as a treatment for molluscum contagiosium. The trial met its primary endpoint and positions Novan to seek FDA approval of SB206 for what is expected to be an at-home, self or caregiver-applied treatment for molluscum, but Verica's Ycanth phase 3 results demonstrate a more consistent and much superior efficacy profile in clearing molluscum lesions, Belanger tells investors in a research note.
|Over a week ago|
Verrica Pharmaceuticals price target lowered to $19 from $24 at Northland » 09:1206/0106/01/21
Northland analyst Tim…
Northland analyst Tim Chiang lowered the firm's price target on Verrica Pharmaceuticals to $19 from $24 in a note published on Friday after the company announced that the FDA's review of VP-102 would be extended by three months to near the end of September. He has adjusted his 2021 estimates to reflect a delay in the expected approval and launch of the company's drug/device combo for treatment of molluscum and keeps an Outperform rating on Verrica shares.
Verrica announces extension of FDA review period for VP-102 NDA » 07:3105/2805/28/21
Verrica Pharmaceuticals announced that the U.S. Food and Drug Administration has extended the review period for the New Drug Application for VP-102 for the treatment of molluscum contagiosum. The Prescription Drug User Fee Act goal date has been extended by three months to September 23, 2021. The FDA extended the PDUFA goal date to allow the Agency to have additional time to review information submitted by Verrica, including its training program and distribution model, in response to comments from the agency regarding the Company's human factors study. On May 26, 2021, the FDA informed Verrica that the information submitted has been designated a major amendment, which allows FDA to take an additional three months to review the submitted information.
|Over a month ago|
Verrica Pharmaceuticals initiated with an Outperform at RBC Capital » 16:2005/1305/13/21
RBC Capital analyst…
RBC Capital analyst Daniel Busby initiated coverage of Verrica Pharmaceuticals with an Outperform rating and $19 price target. Verrica's lead product, YCANTH, has the potential to supplant compounded cantharidin in "several important dermatology markets," argues Busby. He forecasts combined peak sales for YCANTH of about $500M across three indications and sees an "attractive entry point" ahead of the company's upcoming PDUFA date on June 23, Busby added.
Verrica Pharmaceuticals assigned PDUFA goal date of June 23, partners with Torii » 07:4405/0705/07/21
Verrica Pharmaceuticals continued to expand its U.S. commercial operations during the quarter in preparation for the potential FDA approval of VP-102. The company has been assigned a Prescription Drug User Fee Act goal date of June 23, 2021 for its NDA for VP-102. If approved, VP-102 will be marketed in the United States under the conditionally accepted brand name YCANTH. The company entered into a Collaboration and License Agreement with Torii Pharmaceutical granting Torii an exclusive license to develop and commercialize VP-102 in Japan for the treatment of molluscum and common warts. Under the terms of the agreement, Torii made an up-front payment of $11.5M to Verrica and has also agreed to make up to an additional $58M in aggregate payments contingent on achievement of specified development, regulatory, and sales milestones. Torii will also make tiered transfer price payments for supply of product in the range of the mid-30s to mid-40s as a percent of net sales.
Verrica Pharmaceuticals reports Q1 EPS (4c), consensus (35c) » 07:3905/0705/07/21
Reports Q1 licensing…
Reports Q1 licensing revenues 12M. "This is a significant time for the company as we ramp up our commercial readiness plans in preparation for potential FDA approval this year of VP-102 for the treatment of molluscum, a common, highly contagious skin disease with no FDA-approved treatments," said Ted White, Verrica's President and CEO. "In parallel, we strengthened our financial position, raising funds and generating licensing revenues that we believe will support planned operations at least through the second quarter of 2023."
new option listings and one option delisting on May 5th » 08:3005/0505/05/21
AIQ, ASEA, BTX, CIGI, DOOO, EDR, ELDN, FLUX, FSV, GWRS, MYMD, NEBC, SLGL, TARA, VRCA
New option listings for…
New option listings for May 5th include Global X Funds Global X Future Analytics Tech ETF (AIQ), Global X SuperDividend Alternatives (ALTY), Global X Southeast Asia (ASEA), Aspirational Consumer Lifestyle Corp (Class A Stock) (ASPL), Brooklyn ImmunoTherapeutics Inc (BTX), Global X MSCI China Information Technology ETF (CHIK), Colliers International (CIGI), BRP Inc (DOOO), Endeavor Group Holdings Inc (Class A Stock) (EDR), Eledon Pharmaceuticals Inc (ELDN), Fidelity Momentum Factor ETF (FDMO), Fidelity Dividend ETF for Rising Rates (FDRR), Fidelity Core Dividend ETF (FDVV), Fidelity International High Dividend ETF (FIDI), Flux Power Holdings Inc (FLUX), Fidelity Quality Factor ETF (FQAL), Fidelity Small Mid Multifactor ETF (FSMD), FirstService (FSV), Fidelity Value Factor ETF (FVAL), Global Water Resources (GWRS), Global X Thematic Growth ETF (GXTG), Direxion Daily S&P 500 High Beta Bull 3x Shares (HIBL), Global X Conscious Companies (KRMA), Global X Millennials Thematic (MILN), MyMD Pharmaceuticals Inc (MYMD), Nebula Caravel Acquisition Corporation (Class A Stock) (NEBC), Fidelity Nasdaq Composite Index (ONEQ), First Trust Nasdaq Artificial Intelligence and Robotics (ROBT), Global X SuperDividend Emerging Markets ETF (SDEM), Sol Gel Technologies Ltd (SLGL), SVF Investment Corporation (Class A Stock) (SVFA), Protara Therapeutics Inc (TARA), Verrica Parmaceuticals Inc (VRCA), Direxion Daily Consumer Discretionary Bull 3x Shares (WANT), Direxion Daily Dow Jones Internet Bull 3x Shares (WEBL), and Global X S&P 500 Covered Call ETF (XYLD). Option delistings effective May 5th include Valaris Plc (VALPQ).
Verrica Pharmaceuticals 2.034M share Spot Secondary priced at $14.75 » 06:1403/2303/23/21
Jefferies, Cowen and RBC…
Jefferies, Cowen and RBC Capital acted as joint book running managers for the offering.
|Over a quarter ago|
Fly Intel: After-Hours Movers » 18:3803/2203/22/21
BLFS, GHLD, KODK, DSP, RAVN, IONS, XGN, QS, PLL, MP, WES, VRCA
Check out this evening's…
Verrica Pharmaceuticals $30M Spot Secondary re-offered at $14.75 » 16:2703/2203/22/21
Jefferies, Cowen and RBC…
Jefferies, Cowen and RBC Capital are acting as joint book running managers for the offering.